In this article, we will discuss Ramucirumab (21). So, let’s get started. Clinical Trials Experience (2) Ramucirumab Administered as a Single Agent Among 236 patients who received Ramucirumab (safety population) in Study 1, median age was 60 years, 28% were women, 76% were W Hite, and 16% were Asian. Patients in Study 1 received a […]
Category: Ramucirumab
In this article, we will discuss Ramucirumab (20). So, let’s get started. Clinical Trials Experience Clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in […]
In this article, we will discuss Ramucirumab (19). So, let’s get started. Warnings (8) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) RPLS has been reported with a rate of <0.1% in clinical studies with Ramucirumab. Confirm the diagnosis of RPLS with MRI and discontinue Ramucirumab in patients who develop RPLS. Symptoms may resolve or improve within days, […]
In this article, we will discuss Ramucirumab (18). So, let’s get started. Clinical Deterioration in Patients with Child-Pugh B or C Cirrhosis: Clinical deterioration, manifested by new onset or worsening encephalopathy, ascites, or hepatorenal syndrome was reported in patients with Child-Pugh B or C cirrhosis who received single-agent Ramucirumab. Use Ramucirumab in patients with Child-Pugh […]
In this article, we will discuss Ramucirumab (17). So, let’s get started. Warnings (6) Impaired Wound Healing Ramucirumab has not been studied in patients with serious or non-healing wounds. Ramucirumab is an antiangiogenic therapy with the potential to adversely affect wound healing. Withhold Ramucirumab prior to surgery. Resume following the surgical intervention based on clinical […]
In this article, we will discuss Ramucirumab (16). So, let’s get started. Warnings (5) Gastrointestinal Perforations Ramucirumab is an antiangiogenic therapy that can increase the risk of gastrointestinal perforation, a potentially fatal event. Four of 570 patients (0.7%) who received Ramucirumab as a single agent in clinical trials experienced gastrointestinal perforation. In Study 2, the […]